Last reviewed · How we verify
CAR-T
CAR-T cells are engineered T lymphocytes that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens.
CAR-T cells are engineered T lymphocytes that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens. Used for Hematologic malignancies (specific indication under Phase 3 evaluation at Peking University People's Hospital).
At a glance
| Generic name | CAR-T |
|---|---|
| Also known as | anti-CLL1-CD33-NKG2D Bicephali CAR-T cells, CAR-T alone, Chimeric antigen receptor-modified T (CAR-T) cell therapy |
| Sponsor | Peking University People's Hospital |
| Drug class | CAR-T cell therapy |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CAR-T cell therapy involves extracting a patient's T cells, genetically modifying them to express a chimeric antigen receptor (CAR) that targets tumor-associated antigens, and reinfusing the engineered cells to attack and eliminate malignant cells. The CAR combines an extracellular antigen-binding domain with intracellular signaling domains to enable T cell activation and proliferation upon encountering target cancer cells. This approach harnesses the patient's own immune system for personalized cancer treatment.
Approved indications
- Hematologic malignancies (specific indication under Phase 3 evaluation at Peking University People's Hospital)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- A Phase I, Single-arm, Open-label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Cell Infusion in Adult Subjects With Recurrent or Progressive Malignant Primary Brain Tumors（CROWN） (PHASE1)
- Descartes-08 for Patients With Systemic Lupus Erythematosus (PHASE2)
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (PHASE1)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy (PHASE2, PHASE3)
- Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAR-T CI brief — competitive landscape report
- CAR-T updates RSS · CI watch RSS
- Peking University People's Hospital portfolio CI